Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine.
Vaccine shortages are a major obstacle to influenza pandemic preparedness. Increasing vaccine efficiency provides a potentially effective way to overcome this problem. Specifically, using single-dose immunization to induce protective immunity is an attractive approach to emergency/massive vaccination. In this report, we propose a novel nanoemulsion comprised of the bioresorbable polymer, Span 85, and squalene forming a ready-to-use adjuvant, called PELC. After formulation with PELC, inactivated H5N1 virus was intramuscularly administered to mice via a single injection. The data demonstrate that inactivated virus containing 0.5microg hemagglutinin (HA) and formulated with PELC induced more potent antigen-specific antibodies, hemagglutination inhibition, and virus neutralization than non-adjuvanted inactivated virus containing 5microg HA. In addition, T-cell proliferative responses, as well as interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) secretion were significantly enhanced after immunization with PELC-adjuvanted inactivated virus. These results indicate that PELC can be used for effective single-dose immunization and could thus play an important role in influenza pandemic preparedness.
Huang
Ming-Hsi
MH
Vaccine Research and Development Center, National Health Research Institutes, Taiwan, ROC.
Huang
Chiung-Yi
CY
Lin
Su-Chen
SC
Chen
Jia-Huey
JH
Ku
Chien-Chun
CC
Chou
Ai-Hsiang
AH
Liu
Shih-Jen
SJ
Chen
Hsin-Wei
HW
Chong
Pele
P
Leng
Chih-Hsiang
CH
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D016207:Cytokines; D004655:Emulsions / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006601:Hexoses / Q000008:administration & dosage* / Q000494:pharmacology; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000008:administration & dosage; D009500:Neutralization Tests; D013185:Squalene / Q000008:administration & dosage* / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology*; D014452:Ubiquitins; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D016207:Cytokines; D004655:Emulsions; C489550:G1p2 protein, mouse; D006601:Hexoses; D007252:Influenza Vaccines; D014452:Ubiquitins; D015164:Vaccines, Inactivated; D013185:Squalene; C005693:sorbitan trioleate